LRP6 and plasma cell myeloma: Nonetheless, the combination of anti‐LRP6 and anti‐DKK1 antibodies provided superior protection against myeloma‐induced bone loss, as well as providing superior protection against myeloma‐induced vertebral fracture compared to the single treatment approach.